Optimising samples for biomarker testing in lung, prostate and gastric cancer

Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.

Frédéric Bibeau, MD, PhD, is a Professor of Pathology at the head of the Pathology Department of the Besançon University Hospital, Franche-Comté University. He is involved in translational research, in immuno-oncology of solid tumors and in gastrointestinal tumor pathology, notably colorectal cancer, both at the diagnostic and research levels. He is responsible for several long courses in pathology and molecular pathology, notably of the GI tract. Since ten years his work has been focused on rectal cancer, microsatellite unstable colorectal cancer, liver metastases after induction treatment, peritoneal carcinomatosis and predictive factors linked to targeted therapies and immunotherapy. He also involved in national and international groups specialized in rare tumors of the peritoneum. He was one of two coordinators of the BIG-RENAPE network, corresponding to a biological and clinical database dedicated to peritoneal carcinomatosis of digestive origin.

Professor Bibeau is author or co-author of 213 publications. He belongs to the board of national and international journals. He is a member of the French Society of Pathology, the International Academy of Pathology, the French Federation of Digestive Oncology (FFCD). He has been an active member of the European Society of Medical Oncology (ESMO) and the ESMO-Precision-Medicine working group.